title: High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
abstract: OBJECTIVE
  Examination of the rate of grade III or grade IV radiation dermatitis during treatment of head and neck cancer (HNC) with radiotherapy (RT) and concurrent cetuximab in EORTC centres.
  
  
  METHODS
  A questionnaire was sent to all members of the EORTC Radiation Oncology Group and Head and Neck Group (111 institutions) to evaluate the widespread use of cetuximab and radiotherapy in HNC and to estimate the frequency of grades III and IV skin reactions in the radiation portals associated with this protocol. Co-morbidities, RT schedules and co-medications were also recorded.
  
  
  RESULTS
  We received responses from 28 institutions in 11 countries. A total of 125 HNC patients from 15 institutions were treated with cetuximab and concurrent RT. Information about the skin reactions was available from 71 patients. Of these 36 had no grade III/IV adverse effects in the RT field, 15 had a grade III and 20 had grade IV radiation dermatitis. No detectable relation of grades III and IV radiation dermatitis with co-morbidities such as liver insufficiency or renal dysfunction was found.
  
  
  CONCLUSIONS
  According to the results of the questionnaire, grade III/IV radiation dermatitis is observed in 49% of HNC patients treated with cetuximab and concurrent RT. A systematic clinical monitoring of cutaneous side effects during RT plus cetuximab is advised to ensure the safety of this protocol.
authors.affiliation: Department of Radiation Oncology, University Hospital Düsseldorf, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Giro
authors.forename: Bernhard
authors.initials: B
authors.lastname: Berger
authors.forename: Edwin
authors.initials: E
authors.lastname: Bölke
authors.forename: I Frank
authors.initials: IF
authors.lastname: Ciernik
authors.forename: Frederic
authors.initials: F
authors.lastname: Duprez
authors.forename: Laura
authors.initials: L
authors.lastname: Locati
authors.forename: Sophie
authors.initials: S
authors.lastname: Maillard
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.forename: Raphael
authors.initials: R
authors.lastname: Pfeffer
authors.forename: A Gerry
authors.initials: AG
authors.lastname: Robertson
authors.forename: Johannes A
authors.initials: JA
authors.lastname: Langendijk
authors.forename: Wilfried
authors.initials: W
authors.lastname: Budach
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D003625:Data Collection; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D011855:Radiodermatitis / Q000473:pathology*; D011879:Radiotherapy Dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab